Amyris After the Fall:
How a Synthetic Biology Pioneer
Rebuilt Itself From Bankruptcy
Amyris filed for Chapter 11 in 2023, burned through a billion dollars, and shed its consumer brands. Two years on, CEO Kathy Fortmann says the company is a year ahead of plan. The story of its reboot is a case study in what happens when science survives mismanagement — and what the synthetic biology sector must learn from it.
"Our burn rate in all of 2025 was what it was previously in a month. We're a drastically different company."
— Kathy Fortmann, CEO, Amyris, Inc. — May 2026The Collapse: When Science Was Not Enough to Save the Business
Amyris was, for much of the 2010s, the most audacious bet in biotechnology. Founded in 2003, the Emeryville, California company engineered yeast strains to produce complex molecules — artemisinin precursors for antimalarial drugs, squalane for cosmetics, farnesene for fuels — using sugarcane fermentation at industrial scale. It went public on NASDAQ in 2010 under considerable fanfare. By 2022, it had a market capitalisation approaching $3 billion and a consumer brand portfolio spanning celebrity skincare, clean beauty, and nutrition supplements.
Then the architecture collapsed. The consumer brands were consuming capital at a rate the ingredient business could not sustain. The balance sheet, according to its own August 2023 bankruptcy filing, carried an overleveraged structure, mounting litigation risk, deeply unprofitable contracts, and eroding vendor confidence. CEO John Melo resigned in June 2023. Within weeks, Amyris filed for Chapter 11 protection in the Delaware bankruptcy court, listing liabilities estimated between $1 billion and $10 billion against assets of $500 million to $1 billion.
What made the story complicated — and ultimately salvageable — was that the underlying science was not the problem. Every time the name Amyris came up in restructuring conversations, the consensus was the same: great science, broken business model. The company had successfully scaled a number of molecules from laboratory strain to commercial manufacturing — a capability that very few organisations in the world possess end-to-end. That distinction proved decisive.
Amyris's collapse was not a scientific failure. It was a capital allocation failure. The company pursued a vertically integrated consumer brand strategy that required continuous marketing investment at a time when its B2B ingredient economics had not yet reached profitability. The result was a cash burn rate that no amount of revenue growth could outpace. The lesson for the sector is precise: the ability to engineer a molecule is not the same as the ability to commercialise it profitably at consumer scale.
The Reorganisation: From Consumer Brand Portfolio to Pure Biotech
The restructuring was surgical. Amyris divested its consumer brands — including Biossance, JVN, Rose Inc., and a portfolio of celebrity-partnered skincare lines — and shed the associated infrastructure, headcount, and fixed costs. It secured $190 million in debtor-in-possession financing to maintain operations through the Chapter 11 process, followed by a restructured loan agreement providing up to $160 million to underwrite the revitalised business.
By May 2024, the reorganisation was complete. Amyris emerged as a privately held entity, stripped to its core: a vertically integrated synthetic biology company focused exclusively on B2B ingredient manufacturing and technology licensing. Kathy L. Fortmann was appointed CEO, bringing nearly 35 years of experience in specialty chemicals and food ingredients, including senior roles at International Flavors & Fragrances and the chief executive position at Dutch ingredient group ACOMO N.V.
The pivot was not simply a cost reduction exercise. It was a fundamental repositioning of the company's identity — from a consumer-facing food and beauty technology company to a pure B2B biomanufacturing partner for the world's largest ingredient buyers.
The Science That Survived — and Why It Matters
What makes the Amyris reboot strategically significant is not simply that the company avoided liquidation. It is that the core scientific capability — the end-to-end capacity to move from strain engineering to process development to commercial-scale fermentation — remained intact throughout. Most companies that file for bankruptcy at Amyris's scale do not retain this kind of irreplaceable technical infrastructure.
Amyris claims to be the only biotech company that operates across the full spectrum — from strain engineering and process development through to scale-up and commercial production — and has successfully commercialised multiple molecules. That claim is difficult to contest. Prior to bankruptcy, the company had developed, scaled, and commercially launched 16 unique biological or semi-synthesised ingredients, with 33 additional molecules in active development and over 250 in its molecular library.
What made partner companies stay through the bankruptcy process — Givaudan among them — was precisely this manufacturing depth. Designing a molecule is achievable by dozens of synthetic biology firms. Producing it consistently at industrial scale, from fermentation to purified ingredient, in a cost structure that makes commercial sense, is a far smaller club.
The Barra Bonita facility in São Paulo state, Brazil, sits at the centre of this capability. Operating on sugarcane feedstock — one of the most cost-efficient fermentation substrates globally — the plant produces squalane, hemisqualane, farnesene derivatives, vanillin, and Reb M sweeteners across three, soon four, independent fermentation lines. Each line operates with advanced automation and process control that, according to COO Adam Blaziak, enables production with the consistency and traceability that major food and beauty brands now demand as standard.
The fermentation sector is littered with companies that can engineer impressive organisms in the lab but cannot translate that science into reliable, cost-competitive manufacturing at scale. Amyris's 20 years of hard-won process knowledge — including the mistakes that contributed to its bankruptcy — represent a genuine barrier to entry that no startup can easily replicate. For B2B ingredient buyers, that track record is the product.
CEO Fortmann is also signalling openness to a broader commercialisation model. Previously, Amyris required that all partnerships include a direct line of sight to large-scale ingredient manufacturing. The restructured company is more flexible — exploring earlier-stage R&D collaborations, technology licensing, and what analysts are calling Bio-facturing-as-a-Service arrangements, where Amyris's platform and infrastructure are deployed for partners at various stages of commercial readiness.
The Partnerships That Define the New Amyris
The reborn Amyris is not building in isolation. Its commercial architecture is anchored by a series of structured partnerships that replace the consumer-brand revenue model with contracted B2B manufacturing and royalty arrangements. These relationships tell a clearer story of the company's strategic positioning than any single financial metric.
Givaudan acquired the commercial rights to Amyris's Neossance Squalane, Hemisqualane, and CleanScreen portfolio in early 2023, retaining Amyris as the exclusive manufacturer under a long-term supply agreement. This arrangement converted a cash-draining asset into a contracted revenue stream while keeping Amyris's manufacturing infrastructure fully utilised — a critical restructuring bridge.
Following the wind-down of their RealSweet joint venture in 2025, Ingredion gained exclusive commercialisation rights to Amyris's fermented Reb M zero-calorie sweetener technology, with Amyris earning ongoing royalties on future sales. Amyris simultaneously acquired full ownership of the Barra Bonita facility — consolidating control over its manufacturing base while monetising the sweetener IP.
In October 2024, Amyris was awarded a $12.3 million agreement to develop small molecule pharmaceutical compounds, marking a meaningful expansion into high-margin regulated sectors. The contract demonstrates that the company's precision fermentation platform is applicable well beyond food and cosmetics, with GMP manufacturing and specialised drug-delivery molecules identified as growth vectors for 2026 and beyond.
Amyris's 2030 Strategic Plan targets three major Bio-facturing-as-a-Service partnerships by end-2026. The model positions Amyris's Brazil plant and process expertise as a platform that partners can access at various stages — from early R&D through to full commercial-scale production — reducing capital intensity for both parties while leveraging Amyris's hard-won manufacturing know-how.
The pattern across these relationships is consistent with a company that has learned, at significant cost, the value of contracted revenue over consumer market speculation. Each arrangement generates either recurring manufacturing revenue, royalty income, or government-backed R&D funding — all of which compound more predictably than consumer brand marketing spend.
The Market Amyris Is Betting On — and the Scale of the Opportunity
The precision fermentation ingredients market is not a niche. By 2025 estimates, it had reached a value of approximately $5 billion globally, with projections from multiple research houses placing it between $25 billion and $36 billion by 2030 — a compound annual growth rate in the 27–49% range, depending on the methodology applied. Food and beverage is the dominant end-use segment; whey and casein proteins, enzymes, and specialty flavour compounds make up the leading ingredient categories.
The structural drivers of this growth are durable. Consumer demand for sustainable, clean-label, animal-free ingredients is not cyclical — it reflects a multi-decade shift in how global food systems are expected to operate. Regulators in Europe, the US, and increasingly in Asia and the Gulf are building frameworks that favour fermentation-derived alternatives to petrochemical and agriculturally intensive inputs.
For companies like Amyris, the window of opportunity is defined by a specific competitive advantage: the ability to produce molecules at commercial scale, with consistent quality, from renewable feedstocks, at a price point that makes economic sense for industrial buyers. That combination remains rare. The majority of precision fermentation companies are still at pilot or demonstration scale, years away from the manufacturing maturity that Amyris already possesses.
The competitive landscape is also consolidating. Ginkgo Bioworks, one of Amyris's most frequently cited comparators, is focused primarily on cell programming services and biosecurity rather than commercial ingredient manufacturing. Zymergen — acquired by Ginkgo in 2024 after its own bankruptcy — never reached commercial production scale. Perfect Day and The Every Company are focused on animal-free dairy proteins. None occupies precisely the same position as Amyris: a proven, vertically integrated, multi-molecule manufacturer with an operating industrial plant.
Amyris's Brazilian production base provides a structural cost advantage that its US and European competitors cannot easily replicate. Sugarcane, the primary fermentation feedstock at Barra Bonita, is among the world's most efficient sources of fermentable sugars — produced at scale, at low cost, in a regulatory environment favourable to industrial biotech. This feedstock economics advantage translates directly into ingredient pricing competitiveness for Amyris's B2B partners.
Implications for the MENA Region and Saudi Arabia
The Amyris story has direct relevance for investors, food technology operators, and sovereign-backed investment vehicles in the Gulf region — not as a cautionary tale of American biotech excess, but as a precise illustration of the structural questions that regional food systems are beginning to confront.
Saudi Arabia's Vision 2030 food strategy is built on three pillars: increasing domestic production capacity, improving nutritional quality, and reducing the kingdom's structural dependence on imported food commodities. Precision fermentation addresses all three. The ability to produce high-value food and nutritional ingredients — proteins, enzymes, sweeteners, flavour compounds — domestically, from locally available feedstocks, without the land and water intensity of conventional agriculture, is directly aligned with the food security objectives that Riyadh has articulated repeatedly since 2016.
The GCC collectively imports a significant proportion of its food needs. In a region with constrained agricultural land and severe water scarcity, biotechnology-enabled ingredient production is not a future aspiration — it is a logical necessity. The question is not whether precision fermentation arrives in the region, but which entities will own the technology and manufacturing infrastructure when it does.
Saudi Aramco's investment in biotechnology through Wa'ed Ventures, the Saudi Arabian Mining Company's interest in industrial bioprocessing, and NEOM's explicit biotechnology infrastructure plans all point toward a regional appetite for exactly the kind of capability that Amyris represents — vertically integrated, science-led, commercially proven biomanufacturing at industrial scale.
The investment and policy signals from the Amyris reboot are directly applicable to how regional operators should be thinking about their own food technology portfolios:
- Manufacturing infrastructure is the strategic asset — not the brand. Amyris's survival was predicated entirely on the irreplaceable value of its Barra Bonita fermentation infrastructure and its 20 years of process know-how. Regional investors building food technology positions should prioritise manufacturing capability and IP depth over brand value or consumer market share. The lesson from Amyris is that science and manufacturing survive corporate failures; consumer brands rarely do.
- The B2B ingredient model is structurally sounder than consumer brand ownership in deep tech. Amyris's bankruptcy was a consequence of attempting to fund a capital-intensive science platform through consumer brand revenues. The restructured model — contracted manufacturing revenue plus royalty income plus government R&D funding — generates more predictable cash flows and lower marketing exposure. For GCC entities building food tech portfolios, this is the framework worth emulating.
- The precision fermentation supply chain gap in MENA is real and widening. No GCC-based entity currently operates at commercial scale in precision fermentation ingredient production. As global ingredient buyers increasingly demand local supply chain resilience and regional manufacturing redundancy, the absence of a Gulf-based precision fermentation producer represents both a commercial gap and a food security vulnerability. The window for first-mover advantage is open — but finite.
- Sustainable sweeteners are a near-term GCC opportunity. The Reb M sweetener technology that Amyris developed and licensed to Ingredion addresses a market where GCC demand is structurally compelling. Saudi Arabia's national health agenda includes explicit sugar reduction targets, driven by one of the world's highest rates of type-2 diabetes. Fermentation-derived zero-calorie sweeteners — clean-label, natural, scalable — are precisely positioned to serve this regulatory and health direction.
- Bio-manufacturing partnerships are becoming an investment vehicle class. Amyris's Bio-facturing-as-a-Service model — providing manufacturing platform access to partners at various stages of commercial readiness — creates a partnership structure that is relevant to GCC sovereign wealth vehicles and food system investors. Rather than building from scratch, a regional investor could establish a contracted manufacturing relationship with an established precision fermentation operator to localise ingredient production without bearing the full capital burden of building proprietary infrastructure.
Conclusion: Science as the Durable Asset
The Amyris story is, at its core, a story about the difference between what is valuable and what is profitable in the short term. For much of its public life, Amyris chased consumer brand revenues that could not cover the cost of the science platform generating them. The bankruptcy was not an indictment of precision fermentation as a technology — it was an indictment of a capital allocation strategy that misaligned the company's scientific identity with its commercial model.
What the restructured Amyris demonstrates is that the science was always the real asset. The company that emerged in May 2024 — smaller, private, B2B-focused, and manufacturing-led — is a fundamentally more defensible business than the NASDAQ-listed brand conglomerate that preceded it. CEO Fortmann's report that the company closed 2025 a year ahead of plan on both revenue and cost targets, with a monthly burn rate reduced to what the previous entity spent in a single day, is the most concise measure of how complete that transformation has been.
For the precision fermentation sector, the implications are structural. The first wave of synthetic biology companies built platforms; the second wave built brands; the third wave — the one Amyris now exemplifies — builds contracted manufacturing relationships, royalty streams, and platform access models that generate compounding value without the volatility of consumer market exposure. That is the model the sector needed, and the one the Amyris bankruptcy, paradoxically, helped deliver.
